MULTIDISCIPLINARY APPROACH to Oesophageal and gastric cancer



    This book aims at highlighting the present and very dynamic development in the field of pper GI cancers. Oesophageal and gastric cancer are diseases with poor prognosis. Looking back to ous efforts to treat these serious malignancies have been dated already to the ancient periods. The introductory chapter of this issue is therefore dedicated to history of gastric cancer that is tightly connected to history of development of surgical techniques. Surgery remains the basic cornerstone of the treatment of localized oesophageal and gastric cancer and chapters attributed to surgery delineate the sustained development either in classical surgical techniques but also an implementation of new technologies, especially robotic surgery into clinical practice.

    Price: 790 CZK (31EUR),  Pre-order: info@currentmedia.cz




Actual articles

Trifluridine/tipiracil therapy with long‑term effect in the patient with primarily metastatic colorectal cancer – case report

03/2020 Doc. MUDr. Martina Kubecová, Ph.D.
A 71-year-old physician-surgeon in excellent condition, working full-time, with multiple locally advanced colon cancer and synchronous metastatic liver disease, was treated with subtotal colectomy and microwave ablation of liver lesions in 2015. Subsequent systemic therapy was difficult to tolerate, bevacizumab monotherapy only. He was treated with radiotherapy for progression in the liver 2016. Further progression in the liver in 2017 was solved by systemic therapy (irinotecan, cetuximab). For further progression in liver in February 2018, we have used trifluridine/tipiracil therapy, which the patient is still on (February 2020 - 28th cycle). Process stabilization with excellent tolerance has been achieved. The patient is without any problems, still working full-time.

First experience with abemaciclib in real clinical practice – case report

03/2020 MUDr. Dagmar Brančíková, Ph.D.
We describe the case of a 41-year-old patient with breast cancer, where there was primarily surgical liver dissemination and then bone dissemination. The immunoprofile of the hormone-dependent primary tumor was different from the metastasis, which was triplet negative. The patient was treated systemically with hormone therapy with tamoxifen and a combination of cyclin-dependent kinase inhibitors and letrozole. Cyclin-dependent kinase inhibitors were varied according to the adverse event profile. The best tolerated treatment was the combination of abemaciclib with letrozole. Treatment with the combination with denosumab was effective, we achieved partial remission of lung metastases and stabilization of bone.

Efficacy and safety of larotrectinib in patients with TRK‑fusion tumor

03/2020 MUDr. Kateřina Kopečková, Ph.D.
Larotrectinib is a registered anticancer drug for antitumor therapy for tumors with NTRK gene fusions. A published analysis of 159 adult and pediatric patients with solid NTRK fusion tumors treated with larotrectinib showed a median duration of response of 35.2 months and a median time to disease progression of 28.3 months. These were highly heterogeneous groups of advanced pretreated tumors. Larotrectinib has a good safety profile; the dose was reduced in 8% of patient, in 2% due to side effects.